Certificate of Analysis

Report GSA-COA-CUST-BRETT-RETA10-20261105
Issued 2026-11-05 · Page 1 of 2

Scan to verify

Retatrutide 10 mg

Custom sample · Brett


Customer	Brett
Order	Custom sample
Label	Retatrutide 10 mg
Lot	Not provided
Prepared	Whole vial dissolved in 2.00 mL of solvent, then 0.2 mL of that diluted to 1.0 mL (1 in 5)
Tested	5 Nov 2026
Tests	Identity, Purity, Net content, Impurity breakdown

IDENTITY
Retatrutide
confirmed by mass and retention time


PURITY
99.6 %
HPLC-UV, 214 nm, mean of 2 injections

NET CONTENT
12.2 mg
per vial, UV estimate

HPLC chromatogram (UV, 214 nm)



Mass spectrum of the retatrutide peak (first injection, 8.91 min)



Results

Identity	**Consistent with retatrutide.** The main peak at 8.92 min carries retatrutide's 4+ and 5+ ions (m/z 1183.9 and 947.2; molecular mass 4,731.3 and 4,731.1 in the two injections, expected 4,731.3) and elutes within 0.2 % of a retatrutide reference standard run on the same method on 2 Nov 2026 (8.90 min).
Purity	**99.6 %** by HPLC with UV detection at 214 nm, counting every peak: the mean of two injections of the same solution (99.27 % and 99.95 %).
Net content	**12.2 mg per vial** (122 % of the 10 mg label), the mean of two injections that agree within 0.2 %. An estimate by UV absorbance; see below.
How to read this	Purity is a share of the UV peak area, not a weight percentage. This is a development method and has not been validated; impurities that elute together with retatrutide may not be separated from it, so purity can read high. The first injection showed small early peaks (about 0.7 % in total) that were much smaller or absent in the repeat; both injections are counted in the mean. Net content is an estimate: no retatrutide reference standard of known content was available, so it rests on the absorptivity calculated from the sequence and on the volumes used (not weighed). Its uncertainty is roughly ±16 %. Identity is by molecular mass and retention time; the amino-acid sequence was not checked. The raw instrument data for this run follows with the next data upload.

APPROVED FOR RELEASE

Ian Ebert, Laboratory Director

Signed electronically
5 Nov 2026, 23:17 UTC
Release record: last page

Results are not covered by ISO/IEC 17025 accreditation.
Results relate only to the sample as received and tested.


Impurities


Every other peak found. Amounts are % of the UV peak area at 214 nm in the first / second injection (n.d. = not detected):

Peak (min)	Amount	What it is
2.73	0.18 / <0.01	Seen mainly in the first injection; much smaller or absent in the repeat of the same solution, so it is unlikely to be part of the sample. Its mass spectrum is not related to retatrutide.
3.34	0.05 / <0.01	Seen mainly in the first injection; much smaller or absent in the repeat of the same solution, so it is unlikely to be part of the sample. Its mass spectrum is not related to retatrutide.
3.40	0.09 / n.d.	Seen mainly in the first injection; much smaller or absent in the repeat of the same solution, so it is unlikely to be part of the sample. Its mass spectrum is not related to retatrutide.
5.18	0.40 / 0.05	Seen mainly in the first injection; much smaller or absent in the repeat of the same solution, so it is unlikely to be part of the sample. Its mass spectrum is not related to retatrutide.

Trace peaks below 0.05 % add up to < 0.01 % / < 0.01 % in the first / second injection.

Zoomed views





How it was tested

Liquid chromatography with UV and mass-spectrometry detection: Agilent 1290 Infinity II LC with a 6490 triple-quadrupole mass spectrometer. Column Polaris C18-A, 2.0 x 150 mm, 55 °C, 0.300 mL/min; water and acetonitrile, each with 0.1 % formic acid, acetonitrile raised from 34 % to 64 % over 12 minutes. Two injections of 2 µL of the same solution. Purity: UV peak area at 214 nm, every peak counted, after subtracting a blank of the mobile phase run before the sample. Identity: molecular mass from the multiply charged ions in the mass spectrum, and retention time against a retatrutide reference standard run on the same method (2 Nov 2026). Net content: UV absorbance at 280 nm of the retatrutide peak, using the absorptivity calculated from its amino-acid sequence, scaled by the volumes used to dissolve and dilute the vial.

Notes

Results apply only to the sample as received and tested.

APPROVED FOR RELEASE

Signed electronically by a Gold Standard Analytics lab technician at release.
The signature is at the bottom of page 1; the release record, the last page of this certificate, gives the date and verification code.

Gold Standard Analytics

goldstandardanalytics.com

Release record

Report GSA-COA-CUST-BRETT-RETA10-20261105 · Certificate GSA-2026-661570

Customer and order	Brett · Custom sample (no order)
Sample and report	CUST-RETA-20261105 · Retatrutide 10 mg Certificate of Analysis
Report reference	GSA-COA-CUST-BRETT-RETA10-20261105
Certificate accession	GSA-2026-661570
Released and signed by	Ian Ebert, Laboratory Director
Date and time (UTC)	2026-11-05 23:17:41Z
Signature meaning	Approved for release. The signer reviewed this report and approved its release to its customer.
Approval reference	c59cc19d-c3ea-450d-bf29-e6aec4f16144
Electronic signature	Signed electronically in a signed-in GSA staff account.
Original report SHA-256	5b6e2d1982fea1dbdd741246007a46cc92a56e9fb589608ade84f33aaf574890
Verify this certificate	https://goldstandardanalytics.com/coa/GSA-2026-661570

Scan to view this certificate online

Signature



Ian Ebert, Laboratory Director

Results are not covered by ISO/IEC 17025 accreditation. Development method; not validated.
Results relate only to the sample as received and tested.